Navigation Links
Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial
Date:1/27/2009

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today preliminary progression-free survival (PFS) results from its pivotal phase III EXTEND (PIX301) trial of pixantrone that show patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, p < 0.01, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS was a prospectively defined secondary endpoint in the study.

"We always believed the effectiveness of pixantrone would translate into a meaningful difference for patients with relapsed aggressive NHL and these dramatic and significant differences in PFS in this tough to treat group of patients provides that evidence," stated James A. Bianco, M.D. Chief Executive Officer of CTI. "Pixantrone is the first agent in this patient population to demonstrate a significant and meaningful PFS advantage. We believe these data will support a priority review designation on our New Drug Application (NDA) once we share them with the Food and Drug Administration (FDA)."

The Company had previously announced that its pivotal phase III (PIX 301) EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission. Additionally, pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) (26/70 (37.1%) for pixantrone arm compared to 10/70 (
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. Demand for VScan Dengue Fever Test Kits Increases

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... -- BioTrends Research Group, Inc. released Wave 1...the first in a multi-phase syndicated market resea...Biotech,s Stelara, from product launch through the...he report provides quantitative information from 7...n from a subset of 20. The reports assess trial a...
(Date:11/25/2009)... For many of the millions...million living with untreated hearing loss , the ...st Cindy Beyer. ,, Dr. Beyer, senior vice presi...rgest hearing care and hearing aids companies, s...ustration, and social isolation, "which can easily...
(Date:11/25/2009)...PRNewswire/ -- AMPAC Fine Chemicals LLC (AFC), a s... APFC ) announced today that it received the Envi...at the Annual Statewide Environmental Summit, spon...gy Association (CMTA), the Industrial Environmenta...cil of California (CICC) held in San Diego. This ...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Cruise Ship Virus Vaccine Stems From Tobacco 54758 1Cruise Ship Virus Vaccine Stems From Tobacco 54758 2PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 1PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 2PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 3Bankrupt Medicare to be Burdened With 24Billions More for Translation Costs Says ProEnglish 54750 1
...ER, July 28 More research shows that,polyunsatura... in fish,benefit maternal and infant health, immun...he June 2008 Fats of Life and PUFA Newsletter elec...e areas., One study showed that providing greater... PUFA, and arachidonic acid, an omega-6 PUFA, to p...
...Clinical Data Shows Increased Muscle and Blood Ves...s, Hearts, SUNRISE, Fla., July 24 Results of a,p...sts modified to express,stromal derived factor-1(a...myocardium of rats, which suggest improved heart f... meetings -- the International Society for,Magneti...
Other Medicine Technology:Omega-3 Fatty Acids Critical to Infants, Mothers and the Seriously Ill 2Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 2Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 3Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 4Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 5Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 6
(Date:11/27/2009)..., KELOWNA, BC, Nov. 27 /PRNewswire/ - Uploadabl...eeing prime time in wellness. A combination of adv...ta upload are solving a long term concern over the... to accurately gauge and reward improved participa...logies is one of the first wellness suppliers to i...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 /PRNewswire-FirstCall/...unced that Blair Lambert, CFO/COO, will present at...be held at the May Fair Hotel in London, England, ... ,, To listen to a live broadcast of The Gymbor...lease log on to www.gymboree.com, click on "Our Co...
(Date:11/27/2009)..., KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewswire-F... SHMR ) ( "Shamir" ), a leading provider of innov...ns market, announced today that its board of direc...gregate amount of US$ 10 million (approximately NI...resentative rate of exchange), or approximately US...
(Date:11/27/2009)...g rates to bring unprecedented medical, economic b...27 (HealthDay News) -- The number of people with d... over the next 25 years, a new study predicts. ,... million people with the disease, up from 23.7 mil...eating people with diabetes will triple, the study...
(Date:11/27/2009)... Multi-purpose bilingual colori...ned for use by the business community to educate -... subjects from Safety issues to Dinosuars to ABC,S... Saint Louis, MO (PRWEB) November 27, 2009 --...ronics or toys to keep them busy any hour of the d...
Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2
...ASPS Twins Study Finds Environmental Factors Trump...Ill., Feb. 3 Your mother,s wrinkles -- or lack th...l age. In fact, a new study claims just the opposi...ge. Results just published on the web-based versio...
...CORTLANDT MANOR, N.Y., Feb. 3 Polymedco is please...to colorectal cancer statistics and screening. It...ns to risks, statistics, and screening options for...ay in the United States. However, with proper scr...
... FORT WORTH, Texas, Feb. 3 Galderma Laboratori...ug Administration (FDA) has approved,Vectical(TM) ...product for the,treatment of mild-to-moderate plaq...ed, scaly patches of skin and,caused by an abnorma...
...Event to Benefit The Larry King Cardiac Foundation...th Annual Red Dress Awards will commemorate Americ...iduals who have made significant contributions to ... Jazz at Lincoln Center,s Allen Room. The View ...
... MIAMI, Feb. 3 Baker & McKenzie, and Banks...009 Summit aimed at informing investors,in the hea...February 12th at,the Harvard Club. , Internati...Center of Miami and Palm Beach, Florida,( http://w...
...CHICAGO, Feb. 3 The Female Health Company (NYSE A...n investor conference call to discuss its operatin... a.m. Eastern Time (EST) on Tuesday, February 10, ...cipate in the conference call by dialing 800-860-2...
Other Medicine News:Health News:Divorce, Antidepressants, or Weight Gain/Loss Can Add Years to Your Face 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 3Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 4Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 2Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 3Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 4Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 5Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 6Health News:James G. Schwade, M.D. to Deliver Keynote Address to Financial and Investment Industry in New York 2Health News:The Female Health Company Schedules First Quarter Conference Call for February 10, 2009 2
Long Handle Occluder - White
Long Handle Occluder - Black
49 Pinhole short handle
Red Maddox and Red lens
Medicine Products: